Private equity firm Warburg Pincus wants to buy Pantherx Rare from its current owners. Pantherx Rare's current owners are a group of investment firms including General Atlantic, Nautic Partners, and the Vistria Group; Warburg Pincus aims to buy the company from them. To pay for it, Warburg is turning to the bank that dominates Wall Street debt syndication.
Goldman Sachs has joined JPMorgan's lending syndicate for the deal. The total purchase price was not disclosed, but the size of the debt package gives a hint at the scale.
It supplies hard-to-find specialty medicines to pharmacies, which then get them to patients. That niche business is valuable enough that several investment firms want a piece.
The debt package from JPMorgan and its partners will include two layers. First, there is a first-lien loan, which gets repaid before other debt if something goes wrong. Second, there is a second-lien loan, which ranks behind it and carries more risk for lenders.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Preferred equity is a hybrid - part stock, part loan - that sits above common equity but below debt in the payout order.
If Warburg had tried to use a private-credit loan for the new deal instead of bank debt, it would have cost more. A potential private-credit loan would have carried a rate 5 percentage points over the benchmark - half a point higher than the old loan.
That gap shows something interesting. The competition between banks and private-credit shops is alive and well, and for a deal this big, JPMorgan's lower pricing likely won out.
Once Warburg takes over, Pantherx Rare's existing direct-lender loan is expected to be folded into the new capital structure. The old lenders will get paid back or converted as part of the reshuffling.
The debt swap highlights a broader trend: After years of retreating from leveraged lending, banks are reclaiming market share from private-credit funds on large deals. Pantherx Rare's previous $620 million loan from Antares and Blue Owl at a rate 4.5 points above the benchmark was a product of the direct-lending boom. Now, JPMorgan's offer at 5 points for a private-credit alternative shows banks can undercut on pricing for billion-dollar-plus acquisitions.
For most investors, this deal is not something you can directly buy into. But it matters because it reflects a bigger trend in how companies are getting financed.
Banks like JPMorgan are fighting back for big loans after losing ground to private-credit firms. The private-credit market exploded in recent years as banks pulled back from risky lending. Now banks are flexing again on deals over $1 billion, where they can offer cheaper rates than direct lenders.
When a company like Pantherx Rare can borrow a half-point cheaper from a bank than from a private lender, that is real money. Over billions of dollars, half a point saves millions per year in interest.
For investors, this competition can be a good thing. It means companies that need cash have options, and the cost of borrowing may not shoot up as fast as some feared. Lower borrowing costs can keep corporate earnings healthier, and that flows through to stocks and credit markets alike.
The bottom line: a specialty drug distributor just became a test case for whether banks can reclaim territory from private credit. The outcome will ripple into the loans and bonds that show up in many portfolios.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
